Surgical Management of Oligometastatic Non-Small Cell Lung Cancer

Patients harboring stage IV non-small cell lung cancer represent a heterogeneous population with limited life expectancy. Targeted chemotherapy and immunotherapy have improved median survival for a minority of patients. A subset of patients with solitary foci of metastatic disease appears to have improved survival compared to others with stage IV NSCLC. The role of aggressive local control with curative intent for all disease sites in synchronous oligometastatic disease lacks randomized data; however, published retrospective series from single institutions suggest improved survival in highly selected patients (11-30%, 5-year survival) with low morbidity and mortality < 2%.